Francesco Albano
Francesco Albano is an expert in Hematology at University of Bari Aldo Moro (Italy). As of October 2026, ScienceLeadR ranks Francesco Albano in the top 1% of experts worldwide for Leukemia. Francesco Albano has authored 363 publications, the most recent in 2026, and is an investigator in 8 clinical trials. SLR score: 1,153 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 363
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| The Dysregulation of the Integrated Stress Response in Leukemic Stem Cells as a Marker of Treatment Sensitivity in Acute Myeloid Leukemia. PMID 42650147 — cells, activating transcription factor 4, genomics, microscopy, electron, scanning transmission, stress, physiological, leukemia, stem cells, leukemia, myeloid, acute, leukemia, myeloid, therapeutics, dependency, psychological, integrated stress response | Genes (Basel) | 2026 | 0 |
| FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Recommended, but Not Yet Self-Sufficient. PMID 42549694 — leukemia, leukemia, myeloid, acute, leukemia, myeloid, prognosis | Hematol Oncol | 2026 | 0 |
| Effects of immunosuppressive and biological drugs in patients with asymptomatic monoclonal gammopathies (MGUS or smoldering myeloma) and concomitant autoimmune disorders: Results from the real-life MUSA study. PMID 42448329 — hematology, pharmaceutical preparations, smoldering multiple myeloma | Br J Haematol | 2026 | 0 |
| Leukemic architecture as a framework for risk stratification in NPM1-mutated acute myeloid leukemia. PMID 42420551 — cells, leukemia, leukemia, myeloid, acute, leukemia, myeloid, mutation, prognosis | Discov Oncol | 2026 | 0 |
| CAR-T CELLS FATE AFTER INFUSION: CELLULAR KINETICS AND MOLECULAR MONITORING. PMID 42341927 — cells, genes, hematopoietic stem cell transplantation, neoplasms, therapeutics, t-lymphocytes, car-t cell | Transplant Cell Ther | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map